Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 5Lyxumia
02 2Soliqua
03 1Soliqua/Suliqua
04 2Soliqua/iGlarLixi
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Insulin Glargine, Lixisenatide
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 236
2021 Revenue in Millions : 215
Growth (%) : 10
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Diabetes
Currency : USD
2023 Revenue in Millions : 234
2022 Revenue in Millions : 236
Growth (%) : 1
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Diabetes
Currency : USD
2014 Revenue in Millions : 200.00%
2013 Revenue in Millions :
Growth (%) :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Insulin Glargine, Lixisenatide
Main Therapeutic Indication : Diabetes
Currency : USD
2024 Revenue in Millions : 235
2023 Revenue in Millions : 234
Growth (%) : 1
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Diabetes
Currency : USD
2015 Revenue in Millions : 30
2014 Revenue in Millions : 42
Growth (%) : 40%
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Diabetes
Currency : USD
2016 Revenue in Millions : 35
2015 Revenue in Millions : 40
Growth (%) : -13
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Diabetes
Currency : USD
2017 Revenue in Millions : 32
2016 Revenue in Millions : 41
Growth (%) : -21
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Insulin Glargine, Lixisenatide
Main Therapeutic Indication : Diabetes
Currency : USD
2017 Revenue in Millions : 32
2016 Revenue in Millions : 0
Growth (%) : New Launch
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Diabetes
Currency : USD
2018 Revenue in Millions : 0
2017 Revenue in Millions : 29
Growth (%) : -100%
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Insulin Glargine, Lixisenatide
Main Therapeutic Indication : Diabetes
Currency : USD
2018 Revenue in Millions : 82
2017 Revenue in Millions : 29
Growth (%) : 181%
